Skip to main content
Institute for Cardiology Logo Institute for Cardiology

Heart Failure (HFrEF) Pathway

The management of Heart Failure with reduced Ejection Fraction (LVEF ≤ 40%) has undergone a revolution. The historical, slow, sequential addition of drugs has been replaced by the imperative for rapid, simultaneous initiation of four foundational therapies.

1. The Paradigm Shift: Simultaneous Initiation

Historically, clinicians started an ACE inhibitor, titrated to target, then added a beta-blocker, titrated, and so on. This process took 6-9 months, leaving patients exposed to high risks of mortality and readmission. Current guidelines advocate starting all four foundational classes safely within 4 weeks.

2. The Four Pillars of GDMT

Guideline-Directed Medical Therapy (GDMT) for HFrEF consists of four drug classes that independently reduce mortality and hospitalizations. All patients should be on all four unless contraindicated.

1. ARNI (or ACEi/ARB)

Sacubitril/valsartan (Entresto) is preferred over ACEi/ARB based on the PARADIGM-HF trial. Reduces mortality and HF hospitalizations.

2. Beta-Blockers

Bisoprolol, Carvedilol, or Sustained-release Metoprolol succinate. Crucial for anti-arrhythmic and anti-remodeling effects.

3. MRA

Spironolactone or Eplerenone. Aldosterone antagonists that prevent myocardial fibrosis and reduce mortality.

4. SGLT2 Inhibitors

Dapagliflozin or Empagliflozin. Originally diabetes drugs, they offer rapid reduction in cardiovascular death and HF admissions regardless of diabetes status.

3. Rapid Initiation Strategy

Timeline Action (Example Protocol) Checks
Day 0 (Discharge) Start Low-dose Beta-blocker + SGLT2i (10mg) HR > 60, BP > 90/60, eGFR > 20
Week 1-2 Add ARNI (low dose) + MRA (low dose) K+ < 5.0, Creatinine check 1 week post-start
Week 2-4 Up-titrate Beta-blocker and ARNI Symptom check, HR, BP

4. Clinical Monitoring Pitfalls

  • Creatinine Bump: An increase in serum creatinine of up to 30% is expected when starting an ARNI, ACEi, ARB, or SGLT2i. Do not stop the drug unless the rise is severe or accompanied by hyperkalemia.
  • Blood Pressure: Many HFrEF patients run "soft" pressures (systolic 90-100 mmHg). If they are asymptomatic (no dizziness, falls), this is acceptable. Do not withhold GDMT for an asymptomatic low number.
  • Diuretics: Loop diuretics (furosemide) only treat congestion; they do not improve mortality. As you initiate GDMT (especially SGLT2i), diuretic requirements often decrease. Reduce diuretics before stopping GDMT if hypotension occurs.

References

  1. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
  2. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
  3. McMurray JJV, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. (PARADIGM-HF)